Record Quarterly Revenues and an 87% Year-Over-Year  Increase in Cash Flows from Operating Activities to $64.6 Million MONTRÉAL, Nov. 05, 2025 (GLOBE NEWSWIRE) — OR Royalties Inc. (“OR Royalties” or the “Company”) (OR: TSX & NYSE) today announced its consolidated financial results for the third quarter of 2025. Amounts presented are in United States dollars, except where otherwise noted. Highlights20,326 gold equivalent ounces (“GEOs1”) earned (18,408 GEOs in Q3 20242); Revenues from royalties and streams of $71.6 million ($42.0 million in Q3 2024); Cash flows generated by operating activities of $64.6 million ($34.6 million in Q3 2024); Cash margin3 of $69.3 million or 96.7% ($40.4 million or 96.3% in Q3 2024); Net earnings of $82.8 million, $0.44 per basic share ($13.4 million, $0.07 per basic share in Q3 2024); Adjusted...

Dallas, Texas, Nov. 05, 2025 (GLOBE NEWSWIRE) — CompX International Inc. (NYSE American: CIX) announced today net sales of $40.0 million for the third quarter of 2025 compared to $33.6 million in the same period of 2024. Operating income was $4.8 million in the third quarter of 2025 compared to $3.3 million in the same period of 2024. Net income was $4.2 million, or $.34 per basic and diluted common share, for the third quarter of 2025 compared to $3.5 million, or $.28 per basic and diluted common share, in the same period of 2024. For the nine months ended September 30, 2025, net sales were $120.6 million compared to $107.5 million in the previous year. Operating income was $17.0 million for the first nine months of 2025 compared to $12.1 million for the same period in 2024. Net income for the nine months ended September 30,...

Ongoing Phase 1 trial of CTIM-76 (CLDN6 x CD3) demonstrates encouraging antitumor activity and safety Ongoing Phase 1 trial of CT-95 (MSLN x CD3) is approaching target dose levels Cash and cash equivalents of $76.9 million as of September 30, 2025 PHILADELPHIA, Nov. 05, 2025 (GLOBE NEWSWIRE) — Context Therapeutics Inc. (“Context” or the “Company”) (Nasdaq: CNTX), a clinical-stage biopharmaceutical company advancing T cell engaging bispecific antibodies for solid tumors, today provided a clinical update and reported its financial results for the third quarter ended September 30, 2025. “We believe the early clinical data for CTIM-76 provides encouraging early signs of antitumor activity for Context’s T cell engagers (“TCE”) in solid tumors where many other approaches have failed due to material safety issues or lack of efficacy,”...

FAIRPORT, N.Y., Nov. 05, 2025 (GLOBE NEWSWIRE) — Seneca Foods Corporation (NASDAQ: SENEA, SENEB) today announced financial results for the second quarter and six months ended September 27, 2025. Executive Summary (vs. year-ago, year-to-date results):Net sales for the six months ended September 27, 2025 totaled $757.5 million compared to $730.2 million for the six months ended September 28, 2024. The year-over-year increase of $27.3 million was driven by higher sales volumes and the impact of selling prices and product mix. Gross margin as a percentage of net sales is 13.7% for the six months ended September 27, 2025, as compared to 11.7% for the six months ended September 28, 2024.“We are very pleased with our unit volumes and net sales for the quarter, up 10.2% and 8.1%, respectively. We are also enjoying a near budget harvest...

Q3 Net Revenue Increased 45% to $83.6 Million SANTA CLARA, Calif., Nov. 05, 2025 (GLOBE NEWSWIRE) — SiTime Corporation, (Nasdaq: SITM), the Precision Timing company, today announced financial results for the third quarter ended September 30, 2025. Net revenue in the third quarter of 2025 was $83.6 million, as compared to $57.7 million in the year ago quarter. “AI growth powered milestone revenue of $83.6 million in the third quarter with increased adoption of our high-performance, resilient and reliable Precision Timing solutions,” said Rajesh Vashist, chairman and CEO of SiTime. “Given the strength of our Communications-Enterprise-Datacenter business, we expect our rapid growth to continue in upcoming quarters, and to exceed 50% year-over-year for 2025.” In the third quarter of 2025, GAAP gross profit was $44.7 million, or 53.5%...

SAN MATEO, Calif., Nov. 05, 2025 (GLOBE NEWSWIRE) — Freshworks Inc. (Nasdaq: FRSH), the leading provider of uncomplicated software that delivers exceptional customer and employee experiences, today announced financial results for its third quarter ended September 30, 2025. “Freshworks once again exceeded our previously issued estimates across growth and profitability metrics,” said Dennis Woodside, Chief Executive Officer & President of Freshworks. “Business leaders are realizing that AI belongs in the software their teams use every day. They choose Freshworks because our unified platform delivers real productivity gains, not more complexity strains. From intelligent automation across IT and HR to proactive AI-assisted customer support, Freshworks is helping businesses turn intelligence into impact, creating meaningful...

– Topline data from Registrational Expansion Cohort of DELIVER trial of zeleciment rostudirsen (z-rostudirsen, also known as DYNE-251) in DMD on track for December 2025 to support potential submission for U.S. Accelerated Approval in Q2 2026 – – FDA recently granted Breakthrough Therapy Designation to z-rostudirsen for the treatment of patients with DMD amenable to exon 51 skipping – – U.S. sites activated in ACHIEVE trial of zeleciment basivarsen (z-basivarsen, also known as DYNE-101) in DM1; completion of enrollment now expected in early Q2 2026 – – Additional one-year clinical data from ACHIEVE trial demonstrating sustained functional improvement across multiple clinical measures recently presented at WMS – – Reaffirming expected cash runway into Q3 2027, beyond Dyne’s first planned...

Q1 REVENUE OF $1.58B, INCREASED 17% Y/Y AND, ON A PRO FORMA BASIS, 19% Y/Y ADJUSTED FOR SALE OF AEROSPACE & DEFENSE BUSINESS Q1 GAAP GROSS MARGIN OF 36.6%, INCREASED 249 bps Y/Y; Q1 NON-GAAP GROSS MARGIN OF 38.7%, INCREASED 200 bps Y/Y Q1 GAAP EPS OF $1.19, IMPROVED $1.23 Y/Y; Q1 NON-GAAP EPS OF $1.16, IMPROVED $0.49 Y/YSAXONBURG, Pa., Nov. 05, 2025 (GLOBE NEWSWIRE) — Coherent Corp. (NYSE: COHR) (“Coherent,” “We,” or the “Company”), a global leader in photonics, announced financial results today for its first quarter of fiscal year 2026 ended September 30, 2025. Revenue for the first quarter of fiscal 2026 was $1.58 billion, with GAAP gross margin of 36.6% and GAAP net income of $1.19 per diluted share. On a non-GAAP basis, gross margin was 38.7% with net income per diluted share of $1.16. Jim Anderson, CEO, said, “Revenue...

Reported Q3 2025 Total Revenues of $148.4 Million, Driven by Continued FIRDAPSE® Growth, Strong AGAMREE® Uptake and Growth, and Continued Demand for FYCOMPA® Raising Full-Year 2025 Total Revenue Guidance to between $565 Million and $585 Million, Reflecting Better than Originally Forecasted Performance Recently Announced Share Repurchase Program of up to $200 Million, Signaling Confidence in Long-term Outlook Conference Call and Webcast to be Held on Thursday, November 6, 2025, at 8:30 AM ET CORAL GABLES, Fla., Nov. 05, 2025 (GLOBE NEWSWIRE) — Catalyst Pharmaceuticals, Inc. (“Catalyst” or “Company”) (Nasdaq: CPRX) today reported financial results for the third quarter of 2025 and provided a business update. “Throughout 2025, we have continued to execute on our commercial growth initiatives to drive adoption of FIRDAPSE® and AGAMREE®,...

CHICAGO, Nov. 05, 2025 (GLOBE NEWSWIRE) — Sprout Social, Inc. (“Sprout Social”, the “Company”) (Nasdaq: SPT), an industry-leading provider of cloud-based social media management software, today announced financial results for its third quarter ended September 30, 2025. “Our team delivered strong results in the third quarter, highlighted by 17% cRPO growth and strong profitability,” said Ryan Barretto, CEO of Sprout Social. “We saw strong execution in our enterprise segment as we remain committed to strengthening our enterprise presence through customer adoption, account expansion, and strategic partnerships.” Third Quarter 2025 Financial Highlights RevenueRevenue was $115.6 million, up 13% compared to the third quarter of 2024. Total remaining performance obligations (RPO) of $357.1 million as of September 30, 2025, up 15% year-over-year. Current...